Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Ordinary Shares, nominal value Euro 0.04 per share
-
Shares outstanding
-
105,371,575
-
Total 13F shares
-
22,126,805
-
Share change
-
-9,625,041
-
Total reported value
-
$17,208,344
-
Put/Call ratio
-
0%
-
Price per share
-
$0.78
-
Number of holders
-
47
-
Value change
-
-$8,963,813
-
Number of buys
-
22
-
Number of sells
-
32
Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) as of Q2 2022
As of 30 Jun 2022,
ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,126,805 shares.
The largest 10 holders included
Privium Fund Management B.V., ADAGE CAPITAL PARTNERS GP, L.L.C., Opaleye Management Inc., Prosight Management, LP, FIL Ltd, M28 Capital Management LP, JPMORGAN CHASE & CO, Monaco Asset Management SAM, RENAISSANCE TECHNOLOGIES LLC, and MACQUARIE GROUP LTD.
This page lists
47
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.